Orexigen Adding $90M Publicly, Ready for Contrave CVOT Trial
Back in September, Orexigen Therapeutics Inc.'s CEO told BioWorld Today that the firm hoped to avoid a near-term financing by securing an ex-U.S. partnership to help offset costs for the large cardiovascular outcomes trial (CVOT) required by the FDA to get obesity candidate Contrave (naltrexone HCl/bupropion) over the finish line.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter